TICKERNOMICS Sign up
Last Update: 2023-10-04 11:35:26
IBERE PHARMACEUTICALS ( IBER ) https://www.iberepharma.com
10.18USD
Sector:
Financial Services
Industry:
Shell Companies
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
14.73%
IBER
2.62%
SPY
36.71%
IBER
0.00%
SPY
70.96%
IBER
0.00%
SPY
262.36%
IBER
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
175.60
175.60
0.04
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
28.39
0.00
1.32
0.00
0.00
0.00
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
0.00
0.00
0.00
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
4.69
-0.67
-0.68
0.00
Other Earnings and Cash Flow Stats:
IBERE PHARMACEUTICALS ( IBER ) Net Income TTM ($MM) is 6.44
IBERE PHARMACEUTICALS ( IBER ) Operating Income TTM ($MM) is -1.21
IBERE PHARMACEUTICALS ( IBER ) Owners' Earnings Annual ($MM) is 0.00
IBERE PHARMACEUTICALS ( IBER ) Current Price to Owners' Earnings ratio is 0.00
IBERE PHARMACEUTICALS ( IBER ) EBITDA TTM ($MM) is -1.21
IBERE PHARMACEUTICALS ( IBER ) EBITDA Margin is 0.00%
Capital Allocation:
IBERE PHARMACEUTICALS ( IBER ) has paid 0.00 dividends per share and bought back 0.0 million shares in the past 12 months
IBERE PHARMACEUTICALS ( IBER ) has increased its debt by 0.0 million USD in the last 12 months
Capital Structure:
IBERE PHARMACEUTICALS ( IBER ) Interest-bearing Debt ($MM) as of last quarter is 0
IBERE PHARMACEUTICALS ( IBER ) Annual Working Capital Investments ($MM) are -1
IBERE PHARMACEUTICALS ( IBER ) Book Value ($MM) as of last quarter is 133
IBERE PHARMACEUTICALS ( IBER ) Debt/Capital as of last quarter is 0%
Other Balance Sheet Stats:
IBERE PHARMACEUTICALS ( IBER ) has 0 million in cash on hand as of last quarter
IBERE PHARMACEUTICALS ( IBER ) has 0 million of liabilities due within 12 months, and long term debt 0 as of last quarter
IBERE PHARMACEUTICALS ( IBER ) has 17 common shares outstanding as of last quarter
IBERE PHARMACEUTICALS ( IBER ) has 0 million USD of preferred stock value
Academic Scores:
IBERE PHARMACEUTICALS ( IBER ) Altman Z-Score is 0.00 as of last quarter
IBERE PHARMACEUTICALS ( IBER ) Piotroski Score is 2.00 as of last quarter
Corporate Governance:
IBERE PHARMACEUTICALS ( IBER ) largest shareholder is Saba Capital Management, LP owning 355704 shares at 3.62 ($MM) value
(an insider) shares of IBERE PHARMACEUTICALS ( IBER ) for the amount of $ on
0.00% of IBERE PHARMACEUTICALS ( IBER ) is held by insiders, and 98.34% is held by institutions
IBERE PHARMACEUTICALS ( IBER ) went public on 2021-04-20
Other IBERE PHARMACEUTICALS ( IBER ) financial metrics:
FCF:-0.66
Unlevered Free Cash Flow:0.00
EPS:0.18
Operating Margin:0.00
Gross Profit Margin:0.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:2.38
Beta:0.00
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About IBERE PHARMACEUTICALS ( IBER ) :
Ibere Pharmaceuticals does not have significant operations. It focuses on effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses. The company was incorporated in 2020 and is based in Philadelphia, Pennsylvania.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.